Skip to main content

Peer Review reports

From: Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Original Submission
26 May 2021 Submitted Original manuscript
1 Jan 2022 Reviewed Reviewer Report - Riaz Qureshi
25 Feb 2022 Author responded Author comments - Hugh Gallagher
Resubmission - Version 2
25 Feb 2022 Submitted Manuscript version 2
27 Feb 2022 Reviewed Reviewer Report - Riaz Qureshi
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
28 Feb 2022 Editorially accepted
21 Apr 2022 Article published 10.1186/s13063-022-06132-z

You can find further information about peer review here.

Back to article page